Paracoccidioidomycosis overview: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Paracoccidioidomycosis''' ( | '''Paracoccidioidomycosis''' (PCM) is a mycosis caused by the fungus ''[[Paracoccidioides brasiliensis]]'' or ''Paracoccidioides lutzii''. Paracoccidioidomycosis may be classified based on the onset and duration of symptoms. Paracoccidioidomycosis may be classified into acute, subacute or chronic. The chronic form can be further subclassified into unifocal and multifocal.<ref name="pmid26635779">{{cite journal| author=de Oliveira HC, Assato PA, Marcos CM, Scorzoni L, de Paula E Silva AC, Da Silva Jde F et al.| title=Paracoccidioides-host Interaction: An Overview on Recent Advances in the Paracoccidioidomycosis. | journal=Front Microbiol | year= 2015 | volume= 6 | issue= | pages= 1319 | pmid=26635779 | doi=10.3389/fmicb.2015.01319 | pmc=PMC4658449 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26635779 }} </ref><ref name="pmid21738969">{{cite journal| author=Fortes MR, Miot HA, Kurokawa CS, Marques ME, Marques SA| title=Immunology of paracoccidioidomycosis. | journal=An Bras Dermatol | year= 2011 | volume= 86 | issue= 3 | pages= 516-24 | pmid=21738969 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21738969 }} </ref> Spores of ''[[Paracoccidioides brasiliensis|Paracoccidioides spp.]]'' are commonly transmitted via the respiratory route to the human host. Following transmission, ''[[Paracoccidioides brasiliensis|Paracoccidioides spp.]]'' particles invade the terminal bronchioles and alveoli where [[granulomas]] are formed, but can be inactive for up to 40 years.<ref name="pmid21738969">{{cite journal| author=Fortes MR, Miot HA, Kurokawa CS, Marques ME, Marques SA| title=Immunology of paracoccidioidomycosis. | journal=An Bras Dermatol | year= 2011 | volume= 86 | issue= 3 | pages= 516-24 | pmid=21738969 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21738969 }} </ref> On microscopic histopathological analysis, a "pilot's wheel" or a "Mickey mouse ears-like" appearance is a characteristic finding of PCM.<ref>Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016</ref><ref name="?">Manns B.J, Baylis B.W, Urbanski S.J, Gibb A.P, Rabin H.R. Paracoccidioidomycosis: Case Report and Review. ''CID''. 1996; 23: 1026-1032 </ref><ref name="paper">Vargas J, Vargas R. Paracoccidiodomicosis. ''Rev. enferm. infecc. trop.''2009(1):49-56</ref> Among all infected patients 5% are acute with a more rapid and severe progression compared to the chronic subtype. Acute PMC primarily affects the reticuloendothelial system organs.<ref name="pmid22236894">{{cite journal| author=Barreto MM, Marchiori E, Amorim VB, Zanetti G, Takayassu TC, Escuissato DL et al.| title=Thoracic paracoccidioidomycosis: radiographic and CT findings. | journal=Radiographics | year= 2012 | volume= 32 | issue= 1 | pages= 71-84 | pmid=22236894 | doi=10.1148/rg.321115052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22236894 }} </ref><ref name="aaa">Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: An Update. 'Clin. Microbiol. Rev''.1993;6(2):89-117''</ref> Meanwhile, chronic paracoccidioidomycosis represents 90% of infected patients and has a slower progression. Patients with chronic PCM frequently develops pulmonary symptoms.<ref name="a">Vargas J, Vargas R. Paracoccidiodomicosis. ''Rev. enferm. infecc. trop.''2009(1):49-56</ref><ref name="b">Wanke B, Aidê M. Chapter 6 - Paracoccidioidomycosis. ''J. bras. pneumol.'' 2009; 35(12):1245-1249 </ref> Complications that can develop as a result of PCM are [[chronic obstructive pulmonary disease]] (COPD), [[pulmonary fibrosis]], bullae, [[pulmonary hypertension]], [[dyspnea]], [[Addison's disease|adrenal gland insufficiency]], [[dysphonia]], laryngeal lesions (such as glottis estenosis), [[microstomia]], [[seizures]], and motor deficiency.<ref name="aaa">Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: An Update. 'Clin. Microbiol. Rev''.1993;6(2):89-117''</ref><ref name="b">Wanke B, Aidê M. Chapter 6 - Paracoccidioidomycosis. ''J. bras. pneumol.'' 2009; 35(12):1245-1249 </ref><ref name="c">Francesconi F, da Silva MT, Costa RL, et al. Long-term outcome of neuroparacoccidioidomycosis treatment. ''Rev Soc Bras Med Trop.'' 2011;44(1):22-25</ref> The prognosis of paracoccidioidomycosis is good with adequate treatment. Without treatment, death is due to PCM related complications.<ref name="kkk">Martinez, R.Epidemiology of Paracoccidioidomycosis. ''Rev. Inst. Med. trop. S. Paulo.'' 2015;57(19), 11-20</ref> Symptoms of acute PCM include high [[fever]], generalized [[lymphadenopathy]] and pulmonary involvement with milliary lesions. Symptoms of acute PCM include dry cough, dyspnea and asthenia.<ref name=":0">Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016</ref> Patients with [[Acute (medical)|acute]] paracoccidioidomycosis usually appear ill. Chronic PCM patients can appear healthy at early stages. Physical examination of patients with juvenile PCM is usually remarkable for [[lymphadenopathy]] and [[hepatosplenomegaly]]. Adult PCM is characterized by the presence of pulmonary abnormalities and skin lesions.<ref name="a">Vargas J, Vargas R. Paracoccidioidomicosis. ''Rev. enferm. infecc. trop. ''2009;1(1):49-56</ref> Pharmacologic medical therapy is indicated in paracoccidioidomycosis. The preferred regimens for both mild and moderate-to-severe include [[antifungals]] either [[azoles]] (such as [[itraconazole]], [[ketoconazole]], [[voriconazole]]) or [[amphotericin B]] and [[antimicrobials]] such as [[Trimethoprim-Sulfamethoxazole|trimethoprim-sulfamethoxazole]].<ref name="pmid24173174">{{cite journal| author=Marques SA| title=Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. | journal=An Bras Dermatol | year= 2013 | volume= 88 | issue= 5 | pages= 700-11 | pmid=24173174 | doi=10.1590/abd1806-4841.20132463 | pmc=PMC3798345 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24173174 }} </ref> Surgical procedures are usually reserved for patients with PCM sequelae. There are no vaccines and no other primary preventive measures available for paracoccidioidomycosis. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 10: | Line 10: | ||
==Classification== | ==Classification== | ||
Paracoccidioidomycosis may be classified based on the onset and duration of symptoms, paracoccidioidomycosis disease may be classified into | Paracoccidioidomycosis may be classified based on the onset and duration of symptoms, paracoccidioidomycosis disease may be classified into acute, subacute or chronic. The chronic form can be further subclassified into unifocal and multifocal.<ref name="pmid26635779">{{cite journal| author=de Oliveira HC, Assato PA, Marcos CM, Scorzoni L, de Paula E Silva AC, Da Silva Jde F et al.| title=Paracoccidioides-host Interaction: An Overview on Recent Advances in the Paracoccidioidomycosis. | journal=Front Microbiol | year= 2015 | volume= 6 | issue= | pages= 1319 | pmid=26635779 | doi=10.3389/fmicb.2015.01319 | pmc=PMC4658449 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26635779 }} </ref><ref name="pmid21738969">{{cite journal| author=Fortes MR, Miot HA, Kurokawa CS, Marques ME, Marques SA| title=Immunology of paracoccidioidomycosis. | journal=An Bras Dermatol | year= 2011 | volume= 86 | issue= 3 | pages= 516-24 | pmid=21738969 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21738969 }} </ref> | ||
==Pathophysiology== | ==Pathophysiology== | ||
Spores of ''[[Paracoccidioides brasiliensis|Paracoccidioides spp.]]'' are commonly transmitted via the respiratory route to the human host. Following transmission, ''[[Paracoccidioides brasiliensis|Paracoccidioides spp.]]'' particles invade the terminal bronchioles and alveoli where [[granulomas]] are formed, but can be inactive for up to 40 years.<ref name="pmid21738969">{{cite journal| author=Fortes MR, Miot HA, Kurokawa CS, Marques ME, Marques SA| title=Immunology of paracoccidioidomycosis. | journal=An Bras Dermatol | year= 2011 | volume= 86 | issue= 3 | pages= 516-24 | pmid=21738969 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21738969 }} </ref> On microscopic histopathological analysis, a "pilot's wheel" or a "Mickey mouse ears-like" appearance is a characteristic finding of PCM.<ref>Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016</ref><ref name="?">Manns B.J, Baylis B.W, Urbanski S.J, Gibb A.P, Rabin H.R. Paracoccidioidomycosis: Case Report and Review. ''CID''. 1996; 23: 1026-1032 </ref><ref name="paper">Vargas J, Vargas R. Paracoccidiodomicosis. ''Rev. enferm. infecc. trop.''2009(1):49-56</ref> | |||
==Causes== | ==Causes== | ||
| Line 22: | Line 22: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Paracoccidioidomycosis has been reported as an autochthonous | Paracoccidioidomycosis has been reported as an autochthonous disease, that tends to affect agriculture workers from southern Mexico to northern Argentina. Paracoccidioidomycosis is prevalent in Brazil, Colombia, Venezuela, and Argentina, and is classically associated with individuals from rural areas. The typical patient is a man aged 30 to 50 years.<ref>Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2015</ref> PCM affects men, more commonly than women. However, latent [[Paracoccidioides brasiliensis|''paracoccidioides'']] infection can affect anyone.<ref name="pmid21738969">{{cite journal| author=Fortes MR, Miot HA, Kurokawa CS, Marques ME, Marques SA| title=Immunology of paracoccidioidomycosis. | journal=An Bras Dermatol | year= 2011 | volume= 86 | issue= 3 | pages= 516-24 | pmid=21738969 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21738969 }} </ref> | ||
==Risk Factors== | ==Risk Factors== | ||
Common [[risk factors]] in the development of paracoccidioidomycosis disease | Common [[risk factors]] in the development of paracoccidioidomycosis disease include age, gender, poor hygiene, occupation, [[malnutrition]], [[Cigarette smoking|tobacco]] and alcohol consumption.<ref name="pmid26635779">{{cite journal| author=de Oliveira HC, Assato PA, Marcos CM, Scorzoni L, de Paula E Silva AC, Da Silva Jde F et al.| title=Paracoccidioides-host Interaction: An Overview on Recent Advances in the Paracoccidioidomycosis. | journal=Front Microbiol | year= 2015 | volume= 6 | issue= | pages= 1319 | pmid=26635779 | doi=10.3389/fmicb.2015.01319 | pmc=PMC4658449 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26635779 }} </ref><ref name="pmid25076426">{{cite journal| author=Magalhães EM, Ribeiro Cde F, Dâmaso CS, Coelho LF, Silva RR, Ferreira EB et al.| title=Prevalence of paracoccidioidomycosis infection by intradermal reaction in rural areas in Alfenas, Minas Gerais, Brazil. | journal=Rev Inst Med Trop Sao Paulo | year= 2014 | volume= 56 | issue= 4 | pages= 281-5 | pmid=25076426 | doi= | pmc=PMC4131811 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25076426 }} </ref> | ||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
Among all infected patients 5% are acute with a more rapid and severe progression compared to the chronic subtype. Acute PMC primarily affects the reticuloendothelial system organs.<ref name="pmid22236894">{{cite journal| author=Barreto MM, Marchiori E, Amorim VB, Zanetti G, Takayassu TC, Escuissato DL et al.| title=Thoracic paracoccidioidomycosis: radiographic and CT findings. | journal=Radiographics | year= 2012 | volume= 32 | issue= 1 | pages= 71-84 | pmid=22236894 | doi=10.1148/rg.321115052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22236894 }} </ref><ref name="aaa">Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: An Update. 'Clin. Microbiol. Rev''.1993;6(2):89-117''</ref> Meanwhile, chronic paracoccidioidomycosis represents 90% of infected patients and has a slower progression. Patients with chronic PCM frequently develops pulmonary symptoms.<ref name="a">Vargas J, Vargas R. Paracoccidiodomicosis. ''Rev. enferm. infecc. trop.''2009(1):49-56</ref><ref name="b">Wanke B, Aidê M. Chapter 6 - Paracoccidioidomycosis. ''J. bras. pneumol.'' 2009; 35(12):1245-1249 </ref> Complications that can develop as a result of PCM are [[chronic obstructive pulmonary disease]] (COPD), [[pulmonary fibrosis]], bullae, [[pulmonary hypertension]], [[dyspnea]], [[Addison's disease|adrenal gland insufficiency]], [[dysphonia]], laryngeal lesions (such as glottis estenosis), [[microstomia]], [[seizures]], and motor deficiency.<ref name="aaa">Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: An Update. 'Clin. Microbiol. Rev''.1993;6(2):89-117''</ref><ref name="b">Wanke B, Aidê M. Chapter 6 - Paracoccidioidomycosis. ''J. bras. pneumol.'' 2009; 35(12):1245-1249 </ref><ref name="c">Francesconi F, da Silva MT, Costa RL, et al. Long-term outcome of neuroparacoccidioidomycosis treatment. ''Rev Soc Bras Med Trop.'' 2011;44(1):22-25</ref> The prognosis of paracoccidioidomycosis is good with adequate treatment. Without treatment, death is due to PCM related complications.<ref name="kkk">Martinez, R.Epidemiology of Paracoccidioidomycosis. ''Rev. Inst. Med. trop. S. Paulo.'' 2015;57(19), 11-20</ref> | |||
== | == Diagnosis == | ||
== | ===History and Symptoms=== | ||
Symptoms of acute PCM include high [[fever]], generalized [[lymphadenopathy]] and pulmonary involvement with milliary lesions. Symptoms of acute PCM include dry cough, dyspnea and asthenia.<ref name=":0">Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016</ref> | |||
== | ===Physical Examination=== | ||
Patients with [[Acute (medical)|acute]] paracoccidioidomycosis usually appear ill. Chronic PCM patients can appear healthy at early stages. Physical examination of patients with juvenile PCM is usually remarkable for [[lymphadenopathy]] and [[hepatosplenomegaly]]. Adult PCM is characterized by the presence of pulmonary abnormalities and skin lesions.<ref name="a">Vargas J, Vargas R. Paracoccidioidomicosis. ''Rev. enferm. infecc. trop. ''2009;1(1):49-56</ref> | |||
== | ===Laboratory Findings=== | ||
Laboratory findings consistent with the diagnosis of acute PCM include [[anemia]], [[Hypergammaglobulinemia]], [[Eosinophilia]], [[Hypoalbuminemia]], mild increase in [[AST]] and [[ALT]] and conjugated [[hyperbilirubinemia]].<ref name="aaa">Pereira R, Bucaretchi F, Barison E, Hessel G, Tresoldi A. Paracoccidioidomycosis in children: Clinical presentation, follow-up and outcome. ''Rev. Inst. Med. trop. S. Paulo.''2004;46(3):127-131. </ref> | |||
==Medical Therapy== | ===Imaging Findings=== | ||
Common chest x-ray findings in chronic PCM include bilateral and symmetric opacities, butterfly wing pattern, architectural distorsion, paracicatricial [[emphysema]] and traction [[bronchiectasis]]. Chest x-ray finding in acute PCM are characterized by [[mediastinal]] and hiliar [[lymphadenopathy]] and [[pleural effusions]].<ref name="pmid22236894">{{cite journal| author=Barreto MM, Marchiori E, Amorim VB, Zanetti G, Takayassu TC, Escuissato DL et al.| title=Thoracic paracoccidioidomycosis: radiographic and CT findings. | journal=Radiographics | year= 2012 | volume= 32 | issue= 1 | pages= 71-84 | pmid=22236894 | doi=10.1148/rg.321115052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22236894 }} </ref> On thoraxic CT scan, chronic paracoccidioidomycosis is characterized by ground-glass attenuation, airspace consolidations, interlobular septal thickening, nodular pattern, fibrotic pattern, cavitary lesions, [[halo sign]] and reversed halo sign.<ref name="pmid22236894">{{cite journal| author=Barreto MM, Marchiori E, Amorim VB, Zanetti G, Takayassu TC, Escuissato DL et al.| title=Thoracic paracoccidioidomycosis: radiographic and CT findings. | journal=Radiographics | year= 2012 | volume= 32 | issue= 1 | pages= 71-84 | pmid=22236894 | doi=10.1148/rg.321115052 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22236894 }} </ref><ref name="pmid19608361">{{cite journal| author=Marchiori E, Valiante PM, Mano CM, Zanetti G, Escuissato DL, Souza AS et al.| title=Paracoccidioidomycosis: high-resolution computed tomography-pathologic correlation. | journal=Eur J Radiol | year= 2011 | volume= 77 | issue= 1 | pages= 80-4 | pmid=19608361 | doi=10.1016/j.ejrad.2009.06.017 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19608361 }} </ref><ref name="pmid10397100">{{cite journal| author=Funari M, Kavakama J, Shikanai-Yasuda MA, Castro LG, Bernard G, Rocha MS et al.| title=Chronic pulmonary paracoccidioidomycosis (South American blastomycosis): high-resolution CT findings in 41 patients. | journal=AJR Am J Roentgenol | year= 1999 | volume= 173 | issue= 1 | pages= 59-64 | pmid=10397100 | doi=10.2214/ajr.173.1.10397100 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10397100 }} </ref><ref name="pmid17056912">{{cite journal| author=Souza AS, Gasparetto EL, Davaus T, Escuissato DL, Marchiori E| title=High-resolution CT findings of 77 patients with untreated pulmonary paracoccidioidomycosis. | journal=AJR Am J Roentgenol | year= 2006 | volume= 187 | issue= 5 | pages= 1248-52 | pmid=17056912 | doi=10.2214/AJR.05.1065 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17056912 }} </ref> | |||
== Treatment == | |||
===Medical Therapy=== | |||
Pharmacologic medical therapy is indicated in paracoccidioidomycosis. The preferred regimens for both mild and moderate-to-severe include [[antifungals]] either [[azoles]] (such as [[itraconazole]], [[ketoconazole]], [[voriconazole]]) or [[amphotericin B]] and [[antimicrobials]] such as [[Trimethoprim-Sulfamethoxazole|trimethoprim-sulfamethoxazole]].<ref name="pmid24173174">{{cite journal| author=Marques SA| title=Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. | journal=An Bras Dermatol | year= 2013 | volume= 88 | issue= 5 | pages= 700-11 | pmid=24173174 | doi=10.1590/abd1806-4841.20132463 | pmc=PMC3798345 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24173174 }} </ref> | Pharmacologic medical therapy is indicated in paracoccidioidomycosis. The preferred regimens for both mild and moderate-to-severe include [[antifungals]] either [[azoles]] (such as [[itraconazole]], [[ketoconazole]], [[voriconazole]]) or [[amphotericin B]] and [[antimicrobials]] such as [[Trimethoprim-Sulfamethoxazole|trimethoprim-sulfamethoxazole]].<ref name="pmid24173174">{{cite journal| author=Marques SA| title=Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. | journal=An Bras Dermatol | year= 2013 | volume= 88 | issue= 5 | pages= 700-11 | pmid=24173174 | doi=10.1590/abd1806-4841.20132463 | pmc=PMC3798345 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24173174 }} </ref> | ||
==Surgery== | ===Surgery=== | ||
Surgery is not the first-line treatment option for patients with paracoccidioidomycosis. Different surgical procedures are usually reserved for patients with | Surgery is not the first-line treatment option for patients with paracoccidioidomycosis. Different surgical procedures are usually reserved for patients with PCM sequelae. | ||
===Prevention=== | |||
There are no vaccines and no other primary preventive measures available for paracoccidioidomycosis. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 22:15, 12 February 2016
|
Paracoccidioidomycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Paracoccidioidomycosis overview On the Web |
|
American Roentgen Ray Society Images of Paracoccidioidomycosis overview |
|
Risk calculators and risk factors for Paracoccidioidomycosis overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Danitza Lukac
Overview
Paracoccidioidomycosis (PCM) is a mycosis caused by the fungus Paracoccidioides brasiliensis or Paracoccidioides lutzii. Paracoccidioidomycosis may be classified based on the onset and duration of symptoms. Paracoccidioidomycosis may be classified into acute, subacute or chronic. The chronic form can be further subclassified into unifocal and multifocal.[1][2] Spores of Paracoccidioides spp. are commonly transmitted via the respiratory route to the human host. Following transmission, Paracoccidioides spp. particles invade the terminal bronchioles and alveoli where granulomas are formed, but can be inactive for up to 40 years.[2] On microscopic histopathological analysis, a "pilot's wheel" or a "Mickey mouse ears-like" appearance is a characteristic finding of PCM.[3][4][5] Among all infected patients 5% are acute with a more rapid and severe progression compared to the chronic subtype. Acute PMC primarily affects the reticuloendothelial system organs.[6][7] Meanwhile, chronic paracoccidioidomycosis represents 90% of infected patients and has a slower progression. Patients with chronic PCM frequently develops pulmonary symptoms.[8][9] Complications that can develop as a result of PCM are chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, bullae, pulmonary hypertension, dyspnea, adrenal gland insufficiency, dysphonia, laryngeal lesions (such as glottis estenosis), microstomia, seizures, and motor deficiency.[7][9][10] The prognosis of paracoccidioidomycosis is good with adequate treatment. Without treatment, death is due to PCM related complications.[11] Symptoms of acute PCM include high fever, generalized lymphadenopathy and pulmonary involvement with milliary lesions. Symptoms of acute PCM include dry cough, dyspnea and asthenia.[12] Patients with acute paracoccidioidomycosis usually appear ill. Chronic PCM patients can appear healthy at early stages. Physical examination of patients with juvenile PCM is usually remarkable for lymphadenopathy and hepatosplenomegaly. Adult PCM is characterized by the presence of pulmonary abnormalities and skin lesions.[8] Pharmacologic medical therapy is indicated in paracoccidioidomycosis. The preferred regimens for both mild and moderate-to-severe include antifungals either azoles (such as itraconazole, ketoconazole, voriconazole) or amphotericin B and antimicrobials such as trimethoprim-sulfamethoxazole.[13] Surgical procedures are usually reserved for patients with PCM sequelae. There are no vaccines and no other primary preventive measures available for paracoccidioidomycosis.
Historical Perspective
Paracoccidioidomycosis, also known as Lutz-Splendore-de Almeida disease, is named after Adolfo Lutz, Alfonso Splendore, and Floriano Paulo de Almeida, three physicians who first characterized the disease in Brazil in the early 20th century.[14]
Classification
Paracoccidioidomycosis may be classified based on the onset and duration of symptoms, paracoccidioidomycosis disease may be classified into acute, subacute or chronic. The chronic form can be further subclassified into unifocal and multifocal.[1][2]
Pathophysiology
Spores of Paracoccidioides spp. are commonly transmitted via the respiratory route to the human host. Following transmission, Paracoccidioides spp. particles invade the terminal bronchioles and alveoli where granulomas are formed, but can be inactive for up to 40 years.[2] On microscopic histopathological analysis, a "pilot's wheel" or a "Mickey mouse ears-like" appearance is a characteristic finding of PCM.[15][4][5]
Causes
Paracoccidioidomycosis may be caused by either Paracoccidioides brasiliensis or Paracoccidioides lutzii.
Differential Diagnosis
Acute paracoccidioidomycosis must be differentiated from leukemia, lymphoma, toxoplasmosis and sarcoidosis.[4] Chronic paracoccidioidomycosis must be differentiated from tuberculosis, histoplasmosis and metastasis.[16]
Epidemiology and Demographics
Paracoccidioidomycosis has been reported as an autochthonous disease, that tends to affect agriculture workers from southern Mexico to northern Argentina. Paracoccidioidomycosis is prevalent in Brazil, Colombia, Venezuela, and Argentina, and is classically associated with individuals from rural areas. The typical patient is a man aged 30 to 50 years.[17] PCM affects men, more commonly than women. However, latent paracoccidioides infection can affect anyone.[2]
Risk Factors
Common risk factors in the development of paracoccidioidomycosis disease include age, gender, poor hygiene, occupation, malnutrition, tobacco and alcohol consumption.[1][18]
Natural History, Complications and Prognosis
Among all infected patients 5% are acute with a more rapid and severe progression compared to the chronic subtype. Acute PMC primarily affects the reticuloendothelial system organs.[6][7] Meanwhile, chronic paracoccidioidomycosis represents 90% of infected patients and has a slower progression. Patients with chronic PCM frequently develops pulmonary symptoms.[8][9] Complications that can develop as a result of PCM are chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, bullae, pulmonary hypertension, dyspnea, adrenal gland insufficiency, dysphonia, laryngeal lesions (such as glottis estenosis), microstomia, seizures, and motor deficiency.[7][9][10] The prognosis of paracoccidioidomycosis is good with adequate treatment. Without treatment, death is due to PCM related complications.[11]
Diagnosis
History and Symptoms
Symptoms of acute PCM include high fever, generalized lymphadenopathy and pulmonary involvement with milliary lesions. Symptoms of acute PCM include dry cough, dyspnea and asthenia.[12]
Physical Examination
Patients with acute paracoccidioidomycosis usually appear ill. Chronic PCM patients can appear healthy at early stages. Physical examination of patients with juvenile PCM is usually remarkable for lymphadenopathy and hepatosplenomegaly. Adult PCM is characterized by the presence of pulmonary abnormalities and skin lesions.[8]
Laboratory Findings
Laboratory findings consistent with the diagnosis of acute PCM include anemia, Hypergammaglobulinemia, Eosinophilia, Hypoalbuminemia, mild increase in AST and ALT and conjugated hyperbilirubinemia.[7]
Imaging Findings
Common chest x-ray findings in chronic PCM include bilateral and symmetric opacities, butterfly wing pattern, architectural distorsion, paracicatricial emphysema and traction bronchiectasis. Chest x-ray finding in acute PCM are characterized by mediastinal and hiliar lymphadenopathy and pleural effusions.[6] On thoraxic CT scan, chronic paracoccidioidomycosis is characterized by ground-glass attenuation, airspace consolidations, interlobular septal thickening, nodular pattern, fibrotic pattern, cavitary lesions, halo sign and reversed halo sign.[6][19][20][21]
Treatment
Medical Therapy
Pharmacologic medical therapy is indicated in paracoccidioidomycosis. The preferred regimens for both mild and moderate-to-severe include antifungals either azoles (such as itraconazole, ketoconazole, voriconazole) or amphotericin B and antimicrobials such as trimethoprim-sulfamethoxazole.[13]
Surgery
Surgery is not the first-line treatment option for patients with paracoccidioidomycosis. Different surgical procedures are usually reserved for patients with PCM sequelae.
Prevention
There are no vaccines and no other primary preventive measures available for paracoccidioidomycosis.
References
- ↑ 1.0 1.1 1.2 de Oliveira HC, Assato PA, Marcos CM, Scorzoni L, de Paula E Silva AC, Da Silva Jde F; et al. (2015). "Paracoccidioides-host Interaction: An Overview on Recent Advances in the Paracoccidioidomycosis". Front Microbiol. 6: 1319. doi:10.3389/fmicb.2015.01319. PMC 4658449. PMID 26635779.
- ↑ 2.0 2.1 2.2 2.3 2.4 Fortes MR, Miot HA, Kurokawa CS, Marques ME, Marques SA (2011). "Immunology of paracoccidioidomycosis". An Bras Dermatol. 86 (3): 516–24. PMID 21738969.
- ↑ Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016
- ↑ 4.0 4.1 4.2 Manns B.J, Baylis B.W, Urbanski S.J, Gibb A.P, Rabin H.R. Paracoccidioidomycosis: Case Report and Review. CID. 1996; 23: 1026-1032
- ↑ 5.0 5.1 Vargas J, Vargas R. Paracoccidiodomicosis. Rev. enferm. infecc. trop.2009(1):49-56
- ↑ 6.0 6.1 6.2 6.3 Barreto MM, Marchiori E, Amorim VB, Zanetti G, Takayassu TC, Escuissato DL; et al. (2012). "Thoracic paracoccidioidomycosis: radiographic and CT findings". Radiographics. 32 (1): 71–84. doi:10.1148/rg.321115052. PMID 22236894.
- ↑ 7.0 7.1 7.2 7.3 7.4 Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: An Update. 'Clin. Microbiol. Rev.1993;6(2):89-117
- ↑ 8.0 8.1 8.2 8.3 Vargas J, Vargas R. Paracoccidiodomicosis. Rev. enferm. infecc. trop.2009(1):49-56
- ↑ 9.0 9.1 9.2 9.3 Wanke B, Aidê M. Chapter 6 - Paracoccidioidomycosis. J. bras. pneumol. 2009; 35(12):1245-1249
- ↑ 10.0 10.1 Francesconi F, da Silva MT, Costa RL, et al. Long-term outcome of neuroparacoccidioidomycosis treatment. Rev Soc Bras Med Trop. 2011;44(1):22-25
- ↑ 11.0 11.1 Martinez, R.Epidemiology of Paracoccidioidomycosis. Rev. Inst. Med. trop. S. Paulo. 2015;57(19), 11-20
- ↑ 12.0 12.1 Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016
- ↑ 13.0 13.1 Marques SA (2013). "Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating". An Bras Dermatol. 88 (5): 700–11. doi:10.1590/abd1806-4841.20132463. PMC 3798345. PMID 24173174.
- ↑ Paracoccidioidomycosis. Wikipedia. https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016
- ↑ Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2016
- ↑ Manns B.J, Baylis B.W, Urbanski S.J, Gibb A.P, Rabin H.R. Paracoccidioidomycosis: Case Report and Review. CID. 1996; 23:1026-1032
- ↑ Paracoccidioidomycosis. Wikipedia.https://en.wikipedia.org/wiki/Paracoccidioidomycosis. Accessed on January 12, 2015
- ↑ Magalhães EM, Ribeiro Cde F, Dâmaso CS, Coelho LF, Silva RR, Ferreira EB; et al. (2014). "Prevalence of paracoccidioidomycosis infection by intradermal reaction in rural areas in Alfenas, Minas Gerais, Brazil". Rev Inst Med Trop Sao Paulo. 56 (4): 281–5. PMC 4131811. PMID 25076426.
- ↑ Marchiori E, Valiante PM, Mano CM, Zanetti G, Escuissato DL, Souza AS; et al. (2011). "Paracoccidioidomycosis: high-resolution computed tomography-pathologic correlation". Eur J Radiol. 77 (1): 80–4. doi:10.1016/j.ejrad.2009.06.017. PMID 19608361.
- ↑ Funari M, Kavakama J, Shikanai-Yasuda MA, Castro LG, Bernard G, Rocha MS; et al. (1999). "Chronic pulmonary paracoccidioidomycosis (South American blastomycosis): high-resolution CT findings in 41 patients". AJR Am J Roentgenol. 173 (1): 59–64. doi:10.2214/ajr.173.1.10397100. PMID 10397100.
- ↑ Souza AS, Gasparetto EL, Davaus T, Escuissato DL, Marchiori E (2006). "High-resolution CT findings of 77 patients with untreated pulmonary paracoccidioidomycosis". AJR Am J Roentgenol. 187 (5): 1248–52. doi:10.2214/AJR.05.1065. PMID 17056912.